Literature DB >> 9027778

Chinese herbs nephropathy presentation, natural history and fate after transplantation.

F Reginster1, M Jadoul, C van Ypersele de Strihou.   

Abstract

BACKGROUND: Chinese herbs nephropathy is a new type of subacute interstitial nephropathy reported in women who had followed a slimming regimen including Chinese herbs.
METHODS: We report the clinical presentation and follow-up of 15 cases and compare them with a control group of 15 women with interstitial nephropathies of other origins, matched for age, sex, and initial serum creatinine (mean 3 mg/dl).
RESULTS: At presentation the Chinese herbs nephropathy group differed from the control group by a lower proteinuria (P = 0.009), a more severe anaemia (P = 0.002), and a higher prevalence of aortic insufficiency (42% vs 0%, P < 0.05). It was further characterized by mild hypertension in 80%, glycosuria and leukocyturia in 40% and asymmetric kidneys in 54% of the cases. During follow-up, deterioration of renal function was faster in the Chinese herbs nephropathy than in the control group (P < 0.05). It was influenced by the duration of Chinese herbs treatment (P = 0.037) and the delay between the end of Chinese herbs ingestion and diagnosis of the disease (P = 0.013). In three cases, renal failure developed 3 years after Chinese herbs ingestion. Complications included severe aortic regurgitation requiring surgery (n = 1), urothelial carcinoma (n = 2), bilateral ureterohydronephrosis due to periureteral fibrosis (n = 1). Five patients with Chinese herbs nephropathy were successfully transplanted, without evidence of recurrence of the disease.
CONCLUSIONS: Chinese herbs nephropathy is characterized by a lower proteinuria, more severe anaemia, and a faster progression to renal failure than other interstitial nephropathies. The duration of Chinese herbs treatment and interval between withdrawal of Chinese herbs and diagnosis are correlated with the rate of progression. Severe, unusual extrarenal complications may affect Chinese herbs nephropathy patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9027778     DOI: 10.1093/ndt/12.1.81

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

Review 1.  Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment.

Authors:  Randy L Luciano; Mark A Perazella
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

2.  Chinese herb nephropathy.

Authors:  M M Meyer; T P Chen; W M Bennett
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-10

3.  Complementary and alternative medicine use among general surgery, hepatobiliary surgery and surgical oncology patients.

Authors:  Colin Schieman; Luke R Rudmik; Elijah Dixon; Francis Sutherland; Oliver F Bathe
Journal:  Can J Surg       Date:  2009-10       Impact factor: 2.089

Review 4.  Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.

Authors:  Jean-Pierre Cosyns
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety.

Authors:  Martins Ekor
Journal:  Front Pharmacol       Date:  2014-01-10       Impact factor: 5.810

Review 6.  An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature.

Authors:  Inès Jadot; Anne-Emilie Declèves; Joëlle Nortier; Nathalie Caron
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

7.  Effects of aristolochic acid I and/or hypokalemia on tubular damage in C57BL/6 rat with aristolochic acid nephropathy.

Authors:  Joo-Hark Yi; Sang-Woong Han; Wan-Young Kim; Jin Kim; Moon-Hyang Park
Journal:  Korean J Intern Med       Date:  2017-02-15       Impact factor: 2.884

8.  Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology.

Authors:  Linghong Huang; Alessandra Scarpellini; Muriel Funck; Elisabetta A M Verderio; Timothy S Johnson
Journal:  Nephron Extra       Date:  2013-01-11

9.  Role of Terminalia arjuna Wight and Arn. in the treatment of chronic coronary artery disease from pharmacovigilance point of view.

Authors:  Shridhar Dwivedi; Deepti Chopra; Bharti Bhandari
Journal:  Ayu       Date:  2020-03-20

Review 10.  Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges.

Authors:  Hsuan Yeh; Chung-Cheng Chiang; Tzung-Hai Yen
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.